Niraparib: observed
25 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian CancerRecruitingNCT07783022Report a problem
- Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian CancerNot yet recruitingNCT07059676Report a problem
- Niraparib Versus Bevacizumab As Maintenance Therapy in Patients with De Novo Ovarian Cancer Without Homologous Recombination DeficiencyRecruitingNCT06827353Report a problem
- Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.RecruitingNCT06614790Report a problem
- Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian CancerRecruitingNCT06572735Report a problem
- A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of NiraparibRecruitingNCT06037213Report a problem
- Efficacy and Adverse Effects of Niraparib in Ovarian Cancer.Not yet recruitingNCT05583799Report a problem
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated PatientsCompletedNCT07477756Report a problem
- The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian CancerCompletedNCT06086665Report a problem
- A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin AmericaActive, not recruitingNCT05857397Report a problem
- Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world StudyCompletedNCT05734911Report a problem
- Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)Approved for marketingNCT05401214Report a problem
- Homologous Recombination Deficiency in Chinese Ovarian Cancer PatientsStatus unknownNCT05044091Report a problem
- A Study of Niraparib in Patients With Ovarian Cancer in Clinical PracticeCompletedNCT05021562Report a problem
- Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian CancerStatus unknownNCT04986371Report a problem
- Real-life Use of Niraparib in a Patient Access Program in NorwayCompletedNCT04785716Report a problem
- Pancytopenia Related to PARP Inhibitors (PancytoRIB)CompletedNCT04774627Report a problem
- Arterial Hypertension Related to PARP Inhibitors (ArteRIB)CompletedNCT04774406Report a problem
- Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life StudyStatus unknownNCT04617470Report a problem
- A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South KoreaCompletedNCT04589039Report a problem
- The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian CancerStatus unknownNCT04582552Report a problem
- Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian CancerCompletedNCT04546373Report a problem
- Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)CompletedNCT04326023Report a problem
- Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceRCompletedNCT04295577Report a problem
- Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian CancerApproved for marketingNCT03025867Report a problem